Gilead’s Quad May Eventually Face Competition From GSK, Pfizer and Shionogi’s Single Pill

Gilead is looking to maintain its dominance in the HIV market with the introduction of a once-daily complete single tablet regimen for HIV infection called Quad.

Quad would be the first single tablet containing an integrase inhibitor if it is approved for marketing in the U.S. The company could eventually see competition from Viiv (a joint venture between Glaxo- SmithKline and Pfizer) and Shionogi.

Integrase inhibitors prevent the spread of HIV by blocking the virus from binding to the DNA of host cells in a compromised patient. The only-FDA approved integrase inhibitor is Merck’s Isentress (raltegravir).

Read more>>

Bloomberg BRIEF Newsletters